Clinical evaluation of oral levofloxacin 500mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China

Zhang, Yingyuan; Huang, Haihui; Ren, Zhen-yi; Zheng, Hongguang; Yu, Yunsong; Lu, Xin-Jiang; Xiao, Zuke; Yang, Huifen; Xiu, Qingyu; Chen, Bao-yuan; Yue, Hongmei; Hao, Qian; Huang, Jianan; Ma, Hui; Xiao, Wei; Guo, Dongyang; Shu, Bin; Sun, Shenghua; Zhang, Wei; Li, Qihao; Shen, Huahao; Duan, Junchao; Li, Huayin; Yao, Wan-zhen; Gu, Jin; Qian-ming, Xia; Ying, Kejing; Liu, Ao; Yang, Heping; Shi, Minhua; Sun, Tao; Ding, Guohua; Wu, Guohao

doi:10.1007/s10156-009-0713-9

Cited by 16 publications

(21 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the clinical study of LVFX 500 mg once daily for the treatment of CALRTI, including CAP and AECB, the clinical effi cacy rate achieved was 96.4%. 10 For fl uoroquinolones, AUC 0-24h / MIC and C max /MIC are major PK-PD parameters that correlate with therapeutic effi cacy and the prevention of bacterial resistance, respectively. 5,7-9 It has been reported that when the AUC 0-24 /MIC ratio was >30 for Gram-positive bacteria and >100 for Gram-negative bacteria, LVFX achieved good clinical effi cacy.…”

Section: Figmentioning

confidence: 99%

“…10 The most common CALRTIs are CAP and AECB, and this is one of the main issues in public health. The major causative pathogens for CALRTI are S. pneumoniae, MSSA, H. infl uenzae, M. catarrhalis, K. pneumoniae, and atypical bacteria.…”

Section: Figmentioning

confidence: 99%

“…10 Mean C max and AUC 0-24h values of CALRTI patients calculated by Bayesian estimates were used for PK-PD analysis. Based on the MIC 90 values obtained from the clinical study, PK-PD parameters (C max /MIC and AUC 0-24h /MIC) were calculated.…”

Section: Bacteriological Tests and Pk-pd Analysismentioning

confidence: 99%

“…10 As part of this clinical study, a population pharmacokinetic (PPK) study was also conducted to observe the PK characteristics of an LVFX 500-mg once-daily regimen, examined by age, body weight, renal function, and other factors in a Chinese population. The results could provide PK evidence for a rational regimen in the treatment of patients with infections.…”

Section: Mycoplasma Pneumoniae and Chlamydophila Pneumoniaementioning

confidence: 99%

See 3 more Smart Citations

Population pharmacokinetics of oral levofloxacin 500mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China

Zhang

Liu

et al. 2009

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

Section: Figmentioning

confidence: 99%

Section: Figmentioning

confidence: 99%

Section: Bacteriological Tests and Pk-pd Analysismentioning

confidence: 99%

Section: Mycoplasma Pneumoniae and Chlamydophila Pneumoniaementioning

confidence: 99%

See 2 more Smart Citations

Population pharmacokinetics of oral levofloxacin 500mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China

Zhang

Liu

et al. 2009

Journal of Infection and Chemotherapy

Self Cite

View full text Add to dashboard Cite

“…Some infectious diseases such as chronic bacterial prostatitis, lower respiratory tract infections, urinary tract infections and H. pylori infection could be successfully cured by LEV [1][2][3]. The great potency of LEV encouraged several pharmaceutical industries to produce many brands of LEV.…”

Section: Introductionmentioning

confidence: 99%

A Rapid and Simple High-Performance Liquid Chromatographic Method for Determination of Levofloxacin in Human Plasma

et al. 2017

View full text Add to dashboard Cite

show abstract

Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial

Ren

Xiao

et al. 2017

Int Urol Nephrol

View full text Add to dashboard Cite

ObjectiveTo compare the efficacy and safety of short-course intravenous levofloxacin (LVFX) 750 mg with a conventional intravenous/oral regimen of LVFX 500 mg in patients from China with complicated urinary tract infections (cUTIs) and acute pyelonephritis (APN). MethodsThis was a prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial. Patients with cUTI and APN were randomly assigned to a short-course therapy group (intravenous LVFX at750 mg/day for 5 days) or a conventional therapy group (intravenous/oral regimen of LVFX at 500 mg/day for 7–14 days). The clinical, laboratory, and microbiological results were evaluated for efficacy and safety.ResultsThe median dose of LVFX was 3555.4 mg in the short-course therapy group and 4874.2 mg in the conventional therapy group. Intention-to-treat analysis indicated the clinical effectiveness in the short-course therapy group (89.87%, 142/158) was non-inferior to that in the conventional therapy group (89.31%, 142/159). The microbiological effectiveness rates were also similar (short-course therapy: 89.55%, 60/67; conventional therapy: 86.30%, 63/73; p > 0.05). There were no significant differences in other parameters, including clinical and microbiological recurrence rates. The incidence of adverse effects and drug-related adverse effects were also similar for the short-course therapy group (21.95%, 36/164; 18.90%, 31/164) and the conventional therapy group (23.03%, 38/165; 15.76%, 26/165).ConclusionPatients with cUTIs and APN who were given short-course LVFX therapy and conventional LVFX therapy had similar outcomes in clinical and microbiological efficacy, tolerance, and safety. The short-course therapy described here is a more convenient alternative to the conventional regimen with potential implication in anti-resistance and cost saving.Electronic supplementary materialThe online version of this article (doi:10.1007/s11255-017-1507-0) contains supplementary material, which is available to authorized users.

show abstract

Clinical evaluation of oral levofloxacin 500mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China

Cited by 16 publications

References 13 publications

Population pharmacokinetics of oral levofloxacin 500mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China

Population pharmacokinetics of oral levofloxacin 500mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China

A Rapid and Simple High-Performance Liquid Chromatographic Method for Determination of Levofloxacin in Human Plasma

Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial

Contact Info

Product

Resources

About